LearnGlossaryMarketStocksSuperinvestorsSign in

INKT

MiNK Therapeutics, Inc.

Healthcare · $61M market cap

Verdict

We can't put a fair value on INKT right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth—?
Sales growth—?
Free cash flow growth—?
Return on invested capital-78.3%✗

Follow INKT

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 1, 2026: no open-market purchases and 5 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

Corvese Brian

director · 2026-09-01

Award

$18K

Ryan Barbara

director · 2026-09-01

Award

$18K

Behner Peter

director · 2026-09-01

Award

$16K

Holcomb John Bradley

director · 2026-09-01

Award

$14K

WIINBERG ULF

director · 2026-09-01

Award

$14K

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works